Stock Market News3 weeks Merck Halts Second PAH Drug Study Early on Strong Efficacy Results Zacks
MRK’s decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug’s overall clinical program data.
XMRK’s decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug’s overall clinical program data.
X